Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lipocine Inc (LPCN) Fair Value & Analysis

Healthcare · US · Market cap $19.2M

Price$2.47
Fair Value$0.5600
Upside-77.3%
Quality95/100
Evidence: Low Range $0.2500 – $0.9700

Fair value as of: Jun 25, 2026

Analysis

Lipocine Inc (LPCN) currently trades at $2.47, while our model-based Fair Value estimate is $0.5600 — implying the stock looks roughly 77.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In ad…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Lipocine Inc (LPCN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.5600 versus a price of $2.47 — about −77% (overvalued). Model-based estimate, not financial advice.
What is the fair value of LPCN?
Our 21-model fair value for Lipocine Inc is $0.5600 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.47.
What is the quality score of LPCN?
Lipocine Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.